[go: up one dir, main page]

WO2024259078A3 - Anti-tick vaccines and methods of use thereof - Google Patents

Anti-tick vaccines and methods of use thereof Download PDF

Info

Publication number
WO2024259078A3
WO2024259078A3 PCT/US2024/033772 US2024033772W WO2024259078A3 WO 2024259078 A3 WO2024259078 A3 WO 2024259078A3 US 2024033772 W US2024033772 W US 2024033772W WO 2024259078 A3 WO2024259078 A3 WO 2024259078A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
present disclosure
vaccines
vectors
nucleic acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/033772
Other languages
French (fr)
Other versions
WO2024259078A2 (en
Inventor
Matthias Johannes Schnell
Gabrielle Erin SCHER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Publication of WO2024259078A2 publication Critical patent/WO2024259078A2/en
Publication of WO2024259078A3 publication Critical patent/WO2024259078A3/en
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present disclosure relates, in part, to isolated nucleic acids encoding a recombinant virus comprising subolesin (SUB), or a portion thereof, and recombinant viruses and/or vectors comprising the same. The present disclosure further relates to vaccines comprising the isolated nucleic acids, recombinant viruses, and/or vectors of the present disclosure, and methods of use thereof.
PCT/US2024/033772 2023-06-14 2024-06-13 Anti-tick vaccines and methods of use thereof Pending WO2024259078A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363472973P 2023-06-14 2023-06-14
US63/472,973 2023-06-14

Publications (2)

Publication Number Publication Date
WO2024259078A2 WO2024259078A2 (en) 2024-12-19
WO2024259078A3 true WO2024259078A3 (en) 2025-05-30

Family

ID=93852881

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/033772 Pending WO2024259078A2 (en) 2023-06-14 2024-06-13 Anti-tick vaccines and methods of use thereof

Country Status (1)

Country Link
WO (1) WO2024259078A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160051649A1 (en) * 2013-03-29 2016-02-25 Intervet Inc. Vaccine Against Rhipicephalus Ticks
US20220072697A1 (en) * 2016-04-04 2022-03-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Multivalent vaccines for rabies virus and coronaviruses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160051649A1 (en) * 2013-03-29 2016-02-25 Intervet Inc. Vaccine Against Rhipicephalus Ticks
US20220072697A1 (en) * 2016-04-04 2022-03-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Multivalent vaccines for rabies virus and coronaviruses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TRENTELMAN JOS J., TEUNISSEN HENDRY, KLEUSKENS JOS A. G. M., VAN DE CROMMERT JOS, DE LA FUENTE JOSÉ, HOVIUS JOPPE W. R., SCHETTERS: "A combination of antibodies against Bm86 and Subolesin inhibits engorgement of Rhipicephalus australis (formerly Rhipicephalus microplus) larvae in vitro", PARASITES & VECTORS, BIOMED CENTRAL LTD, LONDON UK, vol. 12, no. 1, 1 December 2019 (2019-12-01), London UK , XP093319373, ISSN: 1756-3305, DOI: 10.1186/s13071-019-3616-3 *

Also Published As

Publication number Publication date
WO2024259078A2 (en) 2024-12-19

Similar Documents

Publication Publication Date Title
MX2022010588A (en) Recombinant poxvirus based vaccine against sars-cov-2 virus.
MX2022009962A (en) Vaccines and uses thereof to induce an immune response to sars-cov2.
MXPA02006888A (en) Recombinant flaviviruses and methods of use thereof.
ES2168258T3 (en) RECOMBINANT VIRAL VECTORS CODING FOR HUMAN PAPILOMAVIRUS PROTEINS.
DK0596979T3 (en) Plant virus recombinant nucleic acids
EE05138B1 (en) Recombinant MVA Virus and Its Uses, Isolated Eukaryotic Cell, Method for Recombinant HIV Nef Protein, and Vaccine
CO2020002283A2 (en) Factor viii (fviii) gene therapy methods
WO2004004761A3 (en) Adjuvant viral particle
WO2021000968A3 (en) Adenovirus carrier vaccine used for preventing sars-cov-2 infection
MY131143A (en) Proteins derived from white spot syndrome virus and uses thereof
AU2002337083A1 (en) Vaccinia virus mva-e3l-knockout-mutants and use thereof
WO2014205579A4 (en) Modified matrix proteins of vesicular stomatitis virus
WO2022079160A3 (en) Recombinant hvt and uses thereof
WO2021257510A3 (en) Measles virus vaccine expressing sars-cov-2 protein(s)
MXPA05005549A (en) Recombinant poxvirus comprising at least two cowpox ati promoters.
WO2024259078A3 (en) Anti-tick vaccines and methods of use thereof
WO2004009763A3 (en) Use of vaccinia virus deleted for the e3l gene as a vaccine vector
ZA202310905B (en) Adenoviral vectors encoding hepatitis b viral antigens fused to herpes virus glycoprotein d and methods of using the same
CL2024000820A1 (en) Recombinant vaccine against covid-19 to produce cellular response in individuals with pre-existing immunity
WO2022010860A3 (en) Infectious recombinant vesicular stomatitis virus (rvsv) bearing the spike glycoprotein s of sars-cov-2 and uses thereof
DE60330795D1 (en) VACCINE AGAINST WEST NILE VIRUS
WO2023214082A3 (en) Signal sequences for nucleic acid vaccines
WO2002038769A3 (en) Dna sequences, which code for optimised eukaryotic hpv 16-l1 and hpv 16-l2
RU94030478A (en) Recombinant virus, method of its preparing, immunization method, method of protein preparing, vaccine composition, use of recombinant virus
WO2004104033A3 (en) Viruses dependent on inducing agents for viral entry into a host cell